Society of Nuclear Medicine and Molecular Imaging
@snm-mi.bsky.social
An international scientific and medical organization dedicated to raising public awareness about molecular imaging. Learn more at https://linktr.ee/snmmi
New in JNMT: As nuclear medicine theranostics expands rapidly across clinical practice worldwide, a new supplement explores how nuclear medicine technologists are embracing their growing role within the field.
Learn more and read it here: snmmi.org/Web/News/Art...
Learn more and read it here: snmmi.org/Web/News/Art...
December 8, 2025 at 6:12 PM
New in JNMT: As nuclear medicine theranostics expands rapidly across clinical practice worldwide, a new supplement explores how nuclear medicine technologists are embracing their growing role within the field.
Learn more and read it here: snmmi.org/Web/News/Art...
Learn more and read it here: snmmi.org/Web/News/Art...
Alpha-emitters were effective and well-tolerated to treat refractory patients with DTC -- with either 2.5 or 3.5 MBq/kg, though a dose-limiting toxicity existed at 3.5 MBq/kg. Thyroglobulin was reduced 50% and uptake in radioactive iodine-avid lesions on 131I SPECT decreased.
December 4, 2025 at 5:23 PM
Alpha-emitters were effective and well-tolerated to treat refractory patients with DTC -- with either 2.5 or 3.5 MBq/kg, though a dose-limiting toxicity existed at 3.5 MBq/kg. Thyroglobulin was reduced 50% and uptake in radioactive iodine-avid lesions on 131I SPECT decreased.
Patients with DTC who were refractory to radioactive iodine were given a single intravenous dose of 211At-NaAt.
The study used thyroglobulin measurement, CT imaging, and 131I SPECT to evaluate patient responses.
The study used thyroglobulin measurement, CT imaging, and 131I SPECT to evaluate patient responses.
December 4, 2025 at 5:23 PM
Patients with DTC who were refractory to radioactive iodine were given a single intravenous dose of 211At-NaAt.
The study used thyroglobulin measurement, CT imaging, and 131I SPECT to evaluate patient responses.
The study used thyroglobulin measurement, CT imaging, and 131I SPECT to evaluate patient responses.
What happens when 131I treatment stops working Some patients with recurring or metastatic differentiated thyroid cancer (DTC) stop responding to this treatment.
This first-in-human study used alpha-emitters to treat refractory patients.
jnm.snmjournals.org/content/earl...
This first-in-human study used alpha-emitters to treat refractory patients.
jnm.snmjournals.org/content/earl...
December 4, 2025 at 5:23 PM
What happens when 131I treatment stops working Some patients with recurring or metastatic differentiated thyroid cancer (DTC) stop responding to this treatment.
This first-in-human study used alpha-emitters to treat refractory patients.
jnm.snmjournals.org/content/earl...
This first-in-human study used alpha-emitters to treat refractory patients.
jnm.snmjournals.org/content/earl...
FEATURED: First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:35 PM
FEATURED: First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
FEATURED: PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:35 PM
FEATURED: PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
Is It Really Happening? α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:34 PM
Is It Really Happening? α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
The State of the Art: Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:34 PM
The State of the Art: Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
Discussions with Leaders: Translating Discovery into Impact with Caius Radu
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:34 PM
Discussions with Leaders: Translating Discovery into Impact with Caius Radu
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
The holidays must be here early, because the newest issue of The Journal of Nuclear Medicine is out now! Check out the highlights as our gift to you: jnm.snmjournals.org/content/66/12
December 3, 2025 at 9:33 PM
The holidays must be here early, because the newest issue of The Journal of Nuclear Medicine is out now! Check out the highlights as our gift to you: jnm.snmjournals.org/content/66/12
Being able to personalize a patient's treatment is one of the cornerstones of nuclear medicine, but how are we able to do that? PET-Guided radiotherapy is one answer. Learn more about when to use it in Episode 14 of the JNM Podcast: youtu.be/J1mwyxSfitU
November 24, 2025 at 2:10 PM
Being able to personalize a patient's treatment is one of the cornerstones of nuclear medicine, but how are we able to do that? PET-Guided radiotherapy is one answer. Learn more about when to use it in Episode 14 of the JNM Podcast: youtu.be/J1mwyxSfitU
A 100% Complete Response Rate Shows Promise--85% of mice also achieved histologic cure. 1 and 2-cycle treatments were equally effective and well-tolerated. In the patient xenograft, a single 225Ac treatment achieved a 60% response and prolonged survival compared to no treatment.
November 10, 2025 at 3:27 PM
A 100% Complete Response Rate Shows Promise--85% of mice also achieved histologic cure. 1 and 2-cycle treatments were equally effective and well-tolerated. In the patient xenograft, a single 225Ac treatment achieved a 60% response and prolonged survival compared to no treatment.
Though previous studies have shown that HER2-targeted radiotherapies with the alpha-particle-emitting radionuclide 225Ac were effective, they were not safe for patients, as 225Ac was retained in the body, causing high toxicity.
November 10, 2025 at 3:27 PM
Though previous studies have shown that HER2-targeted radiotherapies with the alpha-particle-emitting radionuclide 225Ac were effective, they were not safe for patients, as 225Ac was retained in the body, causing high toxicity.
Pre-treating a tumor before delivering alpha-radioimmunotherapy has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
jnm.snmjournals.org/content/earl...
jnm.snmjournals.org/content/earl...
November 10, 2025 at 3:27 PM
Pre-treating a tumor before delivering alpha-radioimmunotherapy has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
jnm.snmjournals.org/content/earl...
jnm.snmjournals.org/content/earl...
FEATURED: CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:28 PM
FEATURED: CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction: jnm.snmjournals.org/content/66/1...
FEATURED: 225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:28 PM
FEATURED: 225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer: jnm.snmjournals.org/content/66/1...
The State of the Art: Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:28 PM
The State of the Art: Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages: jnm.snmjournals.org/content/66/1...
Discussions with Leaders: Translating Research Amidst Transnational Quarrels: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:27 PM
Discussions with Leaders: Translating Research Amidst Transnational Quarrels: jnm.snmjournals.org/content/66/1...
It's November — the season of giving thanks — for a new issue of JNM! Here's what's inside this month: 🧵👇
jnm.snmjournals.org
jnm.snmjournals.org
November 4, 2025 at 3:27 PM
It's November — the season of giving thanks — for a new issue of JNM! Here's what's inside this month: 🧵👇
jnm.snmjournals.org
jnm.snmjournals.org
Heart attacks affect nearly one million Americans each year, but what happens after—the healing process—is less well understood. A new PET imaging technique has changed that. Read more in this month’s JNM: jnm.snmjournals.org/content/earl...
October 23, 2025 at 7:29 PM
Heart attacks affect nearly one million Americans each year, but what happens after—the healing process—is less well understood. A new PET imaging technique has changed that. Read more in this month’s JNM: jnm.snmjournals.org/content/earl...
Today for Nuclear Medicine Week, we wanted to give a special shoutout to the 326 nuclear pharmacists who are key in the advancement of our field - particularly for increased access to theranostics. Thank you for your vital contributions!
October 10, 2025 at 2:57 PM
Today for Nuclear Medicine Week, we wanted to give a special shoutout to the 326 nuclear pharmacists who are key in the advancement of our field - particularly for increased access to theranostics. Thank you for your vital contributions!
From atoms to AI-provided answers? The SNMMI AI Task Force is exploring how artificial intelligence can help physician workflow. What task would you give to AI for more patient face time? Let us know 👇
October 8, 2025 at 3:17 PM
From atoms to AI-provided answers? The SNMMI AI Task Force is exploring how artificial intelligence can help physician workflow. What task would you give to AI for more patient face time? Let us know 👇
Join Us in Celebrating Nuclear Medicine Week!
It's time to recognize all the hard work this community does. Join us by sharing your stories, photos, and videos of your work and celebrations!
It's time to recognize all the hard work this community does. Join us by sharing your stories, photos, and videos of your work and celebrations!
October 6, 2025 at 2:23 PM
Join Us in Celebrating Nuclear Medicine Week!
It's time to recognize all the hard work this community does. Join us by sharing your stories, photos, and videos of your work and celebrations!
It's time to recognize all the hard work this community does. Join us by sharing your stories, photos, and videos of your work and celebrations!
FEATURED: Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy 👉https://jnm.snmjournals.org/content/66/10/1622
October 1, 2025 at 9:35 PM
FEATURED: Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy 👉https://jnm.snmjournals.org/content/66/10/1622
FEATURED: Efficacy and Safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 Therapy in Patients with Sarcoma 👉 jnm.snmjournals.org/content/66/1...
October 1, 2025 at 9:35 PM
FEATURED: Efficacy and Safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 Therapy in Patients with Sarcoma 👉 jnm.snmjournals.org/content/66/1...